<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03229499</url>
  </required_header>
  <id_info>
    <org_study_id>827486</org_study_id>
    <secondary_id>R01HL134905</secondary_id>
    <nct_id>NCT03229499</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension and Anastrozole Trial</brief_title>
  <acronym>PHANTOM</acronym>
  <official_title>Pulmonary Hypertension and Anastrozole Trial (PHANTOM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to determine whether the study drug, anastrozole may&#xD;
      improve six minute walk distance at six months compared to placebo and to assess safety and&#xD;
      side effects up to twelve months in pulmonary arterial hypertension (PAH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in changes in distance walked in six minutes between anastrozole and placebo groups</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in distance walked in six minutes between anastrozole and placebo groups</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in right ventricular function between anastrozole and placebo groups</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in plasma NT-proBNP level between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in biomarkers between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in SF36 between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in emPHasis-10 between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in actigraphy-measured physical activity between anastrozole and placebo groups</measure>
    <time_frame>3 months, 6months,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in time-to-clinical worsening (TTCW) between anastrozole and placebo groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in changes in bone mineral density between anastrozole and placebo groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in side effects between anastrozole and placebo groups at twelve months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg (1 tablet)taken by mouth once a day for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet taken by mouth once a day for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole is an aromatase inhibitor indicated for:&#xD;
adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer&#xD;
first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer&#xD;
treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>matching placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous documentation of mean pulmonary artery pressure &gt; 25 mm Hg with a pulmonary&#xD;
             capillary wedge pressure (or left ventricular end-diastolic pressure) &lt; 16 mm Hg and&#xD;
             PVR &gt; 3 WU at any time before study entry.&#xD;
&#xD;
          -  Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated&#xD;
             with connective tissue disease, congenital heart disease, portal hypertension, or HIV&#xD;
             infection and receiving treatment for PAH.&#xD;
&#xD;
          -  Most recent pulmonary function tests with FEV1/FVC &gt;50% AND either a) total lung&#xD;
             capacity &gt; 70% predicted or b) total lung capacity between 60% and 70% predicted with&#xD;
             no more than mild interstitial lung disease on computerized tomography scan of the&#xD;
             chest.&#xD;
&#xD;
          -  Ability to perform six minute walk testing without significant limitations in&#xD;
             musculoskeletal function or coordination.&#xD;
&#xD;
          -  If female, post-menopausal state, defined as:&#xD;
&#xD;
               -  &gt; 50 years old and a) have not menstruated during the preceding 12 months or b)&#xD;
                  have follicle-stimulating hormone (FSH) levels (&gt; 40 IU/L) or&#xD;
&#xD;
               -  &lt; 50 years and FSH (&gt; 40 IU/L) or&#xD;
&#xD;
               -  having had a bilateral oophorectomy.&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18.&#xD;
&#xD;
          -  Current treatment with estrogen, hormone therapy, or anti-hormone therapy (tamoxifen,&#xD;
             fulvestrant, etc.)&#xD;
&#xD;
          -  WHO Class IV functional status.&#xD;
&#xD;
          -  History of invasive breast cancer.&#xD;
&#xD;
          -  Clinically significant untreated sleep apnea.&#xD;
&#xD;
          -  Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency&#xD;
             or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection&#xD;
             fraction &lt; 45% on most recent echocardiography (within 1 year).&#xD;
&#xD;
          -  Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists,&#xD;
             phosphodiesterase-5 inhibitors, riociguat, selexipag) within three months of&#xD;
             enrollment; the dose must be stable for at least three months prior to Baseline Visit.&#xD;
             PAH therapy which is stopped and then restarted or has dose changes which are not&#xD;
             related to initiation and uptitration will be allowed within 3 months prior to the&#xD;
             Baseline Visit.&#xD;
&#xD;
          -  Hospitalized or acutely ill.&#xD;
&#xD;
          -  Renal failure (creatinine â‰¥ 2.0).&#xD;
&#xD;
          -  Hypercalcemia.&#xD;
&#xD;
          -  Severe osteoporosis: T score -2.5 to -3.4 without bone modifying treatment OR T score&#xD;
             = - 3.5 or lower&#xD;
&#xD;
          -  Child-Pugh Class C cirrhosis.&#xD;
&#xD;
          -  Current or recent (&lt; 3 months) chronic heavy alcohol consumption.&#xD;
&#xD;
          -  Enrollment in a clinical trial or concurrent use of another investigational drug or&#xD;
             device within 30 days of screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Kawut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Pinder</last_name>
    <phone>215-294-9757</phone>
    <email>pinder@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Del Rosario, RN</last_name>
      <phone>650-721-2408</phone>
      <email>pdelrosa@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Roham Zamanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado - Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheri Abott, RN, CCRP</last_name>
      <email>Cheryl.Abbott@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Bull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dezeray Cephas</last_name>
      <phone>410-502-4362</phone>
      <email>cephas1@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Mathai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Heuerman, RN</last_name>
      <phone>314-747-8174</phone>
      <email>sheuerman@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Murali Chakinala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tess LaPatra</last_name>
      <phone>215-294-9755</phone>
      <email>Tess.Lapatra@Pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Pinder</last_name>
      <phone>215-294-9757</phone>
      <email>pinder@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Kawut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brynn Normandin</last_name>
      <phone>401-444-2733</phone>
      <email>BNormandin@Lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Corey Ventetuolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Cordell, RN</last_name>
      <phone>615-343-8277</phone>
      <email>shannon.eason@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Anna Hemnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>clinical trial</keyword>
  <keyword>anastrozole</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

